(Q51093650)

29 March 2018

review article

1 reference

title

CCK in anxiety and cognitive processes. (English)

1 reference

29 March 2018

author

Isabelle Léna

series ordinal

2

1 reference

29 March 2018

author name string

Daugé V

series ordinal

1

1 reference

29 March 2018

publication date

1 October 1998

1 reference

29 March 2018

Neuroscience & Biobehavioral Reviews

published in

1 reference

29 March 2018

volume

22

1 reference

29 March 2018

issue

6

1 reference

29 March 2018

page(s)

815-825

1 reference

29 March 2018

Cholecystokinin-4 and panic.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

CCK-4-induced calcium mobilization in T cells is enhanced in panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Effect of ceruletide on pituitary-hypothalamic peptides and on emotion in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Role of different neurotransmitter systems in the cholecystokinin octapeptide-induced anxiogenic response in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Lymphocyte cholecystokinin concentrations in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Enzyme-resistant CCK analogs with high affinities for central receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cyclic cholecystokinin analogues with high selectivity for central receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Anxiolytic effects of CCK-B antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Biological actions of cholecystokinin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The behavioral effects of CCK8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The selective CCK-B agonist, BC 264 injected in the antero-lateral part of the nucleus accumbens, reduces the spontaneous alternation behaviour of rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

A two-trial memory task with automated recording: study in young and aged rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Extension of a new two-trial memory task in the rat: influence of environmental context on recognition processes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Involvement of D2 dopaminergic receptors in the emotional and motivational responses induced by injection of CCK-8 in the posterior part of the rat nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Heterogeneity of CCK-B receptors involved in animal models of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Effect of a highly selective central CCK-B receptor agonist: BC-264 on rat sleep.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Occurrence of two cholecystokinin binding sites in guinea-pig brain cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Discrimination between CCK receptors of guinea-pig and rat brain by cyclic CCK8 analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Further analysis of the effects of cholecystokinin octapeptides on avoidance behaviour in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Modulation of memory processing by cholecystokinin: dependence on the vagus nerve

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

A selective role for dopamine in the nucleus accumbens of the rat in random foraging but not delayed spatial win-shift-based foraging.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Is aging preprogrammed? Observations from the brain/gut axis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Behavioral effects of the cyclic cholecystokinin peptide analogue JMV-320.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Analysis of variation in L-365,260 competition curves in radioligand binding assays

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin receptors and memory: a radial maze study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin peptides and receptors in the rat brain during stress

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Impairment of stress adaptive behaviours in rats by the CCKA receptor antagonist, devazepide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Species differences in the localization of 'peripheral' type cholecystokinin receptors in rodent brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Evidence for coexistence of dopamine and CCK in meso-limbic neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Interactions of cholecystokinin, beta-endorphin, and their antagonists on passive avoidance behavior in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Memory effect of caerulein and its analogs in active and passive avoidance responses in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Effect of the selective CCKB receptor antagonist LY288513 on conditioned fear stress in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The CCKB antagonist, L-365,260, attenuates fear-potentiated startle.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin and Pancreozymin, one single Hormone?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Preventive effect of cholecystokinin octapeptide on experimental amnesia in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Activation of CCK-A receptors induces elevation of plasma corticosterone in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Dopaminergic involvement in attention. A novel animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Effects of CCK8 and of the CCKB-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: a microdialysis study in freely moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The transfer of rats from a familiar to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Mesocorticolimbic dopaminergic network: functional and regulatory roles

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

A comparison of the effects of intravenous pentagastrin on patients with social phobia, panic disorder and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Stress and cognitive function.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Pathway of inactivation of cholecystokinin octapeptide (CCK-8) by synaptosomal fractions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin in the medial parvocellular subdivision of the paraventricular nucleus. Co-existence with corticotropin-releasing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Two brain cholecystokinin receptors: implications for behavioral actions.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The ascent of cholecystokinin (CCK) — From gut to brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat: prevention by diazepam but not ondansetron.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Autoradiography of CCK receptors in the rat brain using [(3)H]Boc[Nle(28)(31)]CCK(27)-(33) and [(125)I]bolton-hunter CCK(8). Functional significance of subregional distributions.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin, gastrin and stress hormone responses in marathon runners

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Evaluation of the effects of PD 134308 (CI-988), A CCK-B antagonist, on the punished responding of squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The benzodiazepine receptor inverse agonist FG 7142 induces cholecystokinin gene expression in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin and anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Characterization and inhibition of a cholecystokinin-inactivating serine peptidase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

A comparative study on characterization and distribution of cholecystokinin binding sites among the rat, mouse and guinea pig brain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal systems to stress, in the male rat

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Stress-induced changes in cholecystokinin and substance P concentrations in discrete regions of the rat hypothalamus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Evidence for an involvement of the brain cholecystokinin B receptor in anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Alternation behavior, spatial discrimination, and reversal disturbances following 6-hydroxydopamine lesions in the nucleus accumbens of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cognitive enhancing effects in young and old rats of pBC264, a selective CCK(B) receptor agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Pretreatment with caerulein protects against memory impairment induced by protein kinase C inhibitors in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Application of 'nose-poke habituation' validation with post-trial diazepam- and cholecystokinin-induced hypo- and hypermnesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Tyrosine hydroxylase-, neurotensin-, or cholecystokinin-containing neurons in the nucleus tractus solitarii send projection fibers to the nucleus accumbens in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

On the significance of subterritories in the "accumbens" part of the rat ventral striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

Spatial localization in the Morris water maze in rats: acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-7634%2898%2900011-6

7 January 2021

10.1016/S0149-7634(98)00011-6

Identifiers

DOI

1 reference

29 March 2018

PubMed ID

9809313

1 reference

29 March 2018